John Neylan

John Neylan has a strong background in the medical field, with over 30 years of experience. John currently holds the role of Executive Vice President & Chief Medical Officer at Akari Therapeutics, Plc since November 2022. Prior to this, they served as the Executive Vice President, Head of Research & Chief Medical Officer at Angion Biomedica Corp. from December 2018 to August 2022. Before that, they were the Senior Vice President and Chief Medical Officer at Keryx Biopharmaceuticals from April 2015 to December 2018. From August 2011 to April 2015, John worked at Genzyme Corporation, A Sanofi Company, where they held various senior leadership positions focused on therapeutic areas such as personalized genetic health and renal and solid organ transplant. Earlier in their career, they were a Vice President at Wyeth Research and held academic positions at Emory University School of Medicine and the University of California, Davis. Overall, John Neylan has a diverse and extensive work experience in the medical and biopharmaceutical industry.

John Neylan has a Bachelor of Science degree in Zoology from Duke University, obtained from 1971 to 1975. John then pursued a Doctor of Medicine (MD) from Rush Medical College of Rush University Medical Center, completing it in the years 1975 to 1979. Following that, they undertook an internship in Medicine at Vanderbilt University School of Medicine in 1979 to 1980, and became a Resident in Internal Medicine from 1980 to 1982 at Vanderbilt University School of Medicine as well. Subsequently, they attended Harvard Medical School starting from 1983 to 1986, where they served as a Clinical Fellow in Nephrology from 1983 to 1984 and then as a Research Fellow in Transplantation & Immunogenetics from 1984 to 1986. John also appears to have some association with Harvard University, although the details are not specified.